Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2023 16:01 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March

SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...
February 22, 2023 16:30 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals Announces Strategic Reprioritization, Continues Focus on Maximizing Trudhesa® Commercial Opportunity

Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 PercentCompany will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales Representatives and Other Commercial...
November 14, 2022 08:00 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million Trudhesa surpasses 5% of Acute Branded Prescriptions among prescribers in Q3 One Year...
November 08, 2022 16:21 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals to Participate in Guggenheim 4th Annual Immunology and Neurology Day

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
November 07, 2022 16:01 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
September 06, 2022 08:00 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in September

SEATTLE, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...
August 15, 2022 08:05 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Trudhesa® TRx’s Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59% Over Q1 2022 to $2.8 Million Sales Force Expanded by 50% to Capitalize on Prescription Momentum and Market...
August 08, 2022 08:00 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
August 02, 2022 08:00 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare Conference

SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases...
July 19, 2022 08:00 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in Adolescents With Autism Spectrum Disorder (ASD)

CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation in Participants with ASD SEATTLE, July 19, 2022 (GLOBE NEWSWIRE) --...